These findings highlight the need for policy interventions to address socioeconomic disparities. Ensuring equitable access to biologics for all patients with RA, regardless of their SES, is crucial for optimal disease management and favorable patient outcomes. To address the socioeconomic disparities in biologics use among patients with RA, policy interventions should focus on minimizing barriers associated with low SES, enhancing control of disease activity, and increasing access to biologics for patients with low SES.
Healthcare providers should play a proactive role in addressing these disparities. By understanding the SES of patients, clinicians can provide more personalized care that considers the financial and educational barriers to treatment. Furthermore, improving health literacy and fostering a supportive environment for treatment adherence are crucial.
This study enhances our understanding on the influences of socioeconomic factors on the utilization of biologics in the treatment of RA. It highlights the need for policymakers and healthcare providers to address the inequities within healthcare systems. Fostering a more equitable approach to RA management can ensure that all patients, regardless of their SES, can benefit from advancements in biologics. The pursuit of healthcare equity is crucial not only for achieving social justice but also for improving overall health outcomes in society. By prioritizing equity and inclusivity in healthcare policies and practices, high-quality healthcare can be provided to all individuals, regardless of their SES.
留言 (0)